Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS Dr Julian Bertschinger Chief Executive Officer Dr Dragan Grabulovski Chief Scientific Officer Dr Fabian Buller Director Business Development ADDRESS Covagen AG Wagistrasse 25 Schlieren, 8952 Switzerland TELEPHONE +41 44 732 46 60 FAX +41 44 732 46 64 EMAIL info@covagen.com YEAR FOUNDED 2007 Covagen AG www.covagen.com FINANCIAL SUMMARY Investors: • Novartis Venture Fund • Edmond de Rothschild Investment Partners • Ventech • Seroba Kernel Life Sciences • MP Healthcare Venture Management COMPANY PROFILE Covagen is a privately held company pioneering the commercialization of Fynomers and bispecific Fynomerantibody fusions (FynomAbs) as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers are small binding proteins that can be engineered to bind to any antigen of interest. Because of their excellent biophysical properties, Fynomers can be readily fused to therapeutic proteins such as antibodies to create bispecific FynomAbs. FynomAbs have novel modes of action as they can engage simultaneously with multiple antigens or multiple binding sites on the same target. At the same time, FynomAbs maintain the advantageous drug-like properties of antibodies such as excellent stability and long half-life. Covagen’s lead program is a bispecific TNF/IL-17 inhibitor (in preclinical development) for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis and rheumatoid arthritis. MANAGEMENT Board of Directors Frank Walsh, Executive Chairman Ray Hill, Franz Hefti, Anja König, Gilles Nobécourt, Mounia Chaoui, Jon Hepple, Julian Bertschinger Scientific Advisory Board Greg Winter, Ulrich Feige, Thierry Hercend, Christoph Heusser, Christoph Lengauer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Mike Romanos PhD Chief Executive Officer ADDRESS Meditrina Building 260 Babraham Research Campus- Cambridge CB22 3AT TELEPHONE +44 1223 497143 FAX +44 1223 497141 EMAIL mromanos @crescendobiologics.com YEAR FOUNDED 2009 Crescendo Biologics Limited www.crescendobiologics.com FINANCIAL SUMMARY Funding to date: GBP 7.7m Investors: • Sofinnova Partners • Babraham Bioscience Technologies • Avlar BioVentures • Rainbow Seed Fund COMPANY PROFILE Crescendo Biologics has developed a novel antibody fragment discovery platform which generates fully human VH fragments by immunisation of a transgenic mouse. The company’s strategy is to utilise the platform in the key value areas for the smallest and most robust antibody fragments, especially in topical products and bi-specifics. It intends to exploit its unique capabilities to create differentiated medicines both through its in-house pipeline and through strategic partnerships. The Crescendo mouse platform was conceived at the Babraham Institute, Cambridge, by Dr Marianne Bruggemann, a pioneer in the field who was the first to engineer transgenic mice to produce human antibodies. It is based on the generation of human heavy chain antibodies by transgenic mice, analogous to similar antibodies produced naturally in llamas. However in this case they are fully human and provide candidate-quality VH fragments directly. VH fragments are the smallest portions of immunoglobulin that retain target specificity and potency and, compared to whole antibodies, have properties more akin to small molecules, making them highly attractive therapeutic agents. The company benefits from a management team that is highly experienced in all aspects of antibody platforms, antibody discovery and development, and the support of a syndicate of experienced life science investors led by Sofinnova Partners. It is based at the Babraham Research Campus and maintains strong links with the Babraham Institute and the antibody science community in Cambridge. MANAGEMENT Mike Romanos PhD, CEO Matthew Roe, Chief Business Officer Amanda Bettison, Head of Business Operations Clive Dix PhD, Chairman t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43: CONTACT Wolfgang Kintzel Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?